IPO · 2026-05-19

Disciplinary Actions by HKEX: Public Censure and Director Unsuitability Statements

The Hong Kong Exchange and Clearing Limited (HKEX) has escalated its disciplinary enforcement in 2025, issuing a record 14 public censures and 8 director unsuitability statements in the first half of the year alone, a 75% increase compared to the same period in 2024. This shift, driven by the Listing Division’s enhanced surveillance capabilities under the revised Listing Rules effective January 2025, targets directors and sponsors for failures in disclosure, internal controls, and conduct during IPOs and continuing obligations. For CFOs, company secretaries, and IBD analysts, the implications are immediate: the HKEX now routinely names individuals in unsuitability statements, effectively barring them from serving on the boards of listed issuers for up to five years. The SFC’s parallel enforcement actions, including a 2024 case where a sponsor was fined HKD 45 million for due diligence failures under the Code of Conduct for Persons Licensed by or Registered with the SFC (Chapter 571), reinforce a regime where personal accountability is the new baseline. This article dissects the mechanics of HKEX disciplinary actions, the triggers for public censure and unsuitability statements, and the practical steps issuers and intermediaries must take to avoid becoming the next enforcement statistic.

The Mechanics of HKEX Disciplinary Powers

Statutory and Rule-Based Foundations

The HKEX derives its disciplinary authority from the Listing Rules (Main Board Rules, Chapter 2A; GEM Rules, Chapter 3A), which empower the Listing Committee to impose sanctions for breaches of listing obligations. Under Main Board Rule 2A.09, the Exchange may issue a public censure, a private reprimand, or a statement of unsuitability against a director. The latter, codified in Rule 2A.09(5), declares that the individual is “unsuitable to remain as a director” of any listed issuer, effectively a blacklisting mechanism. The SFC’s Securities and Futures Ordinance (SFO, Cap. 571) Section 213 provides parallel powers for court-ordered remedies, including disqualification orders, which the SFC has increasingly used in tandem with HKEX actions.

In 2024, the HKEX published 22 disciplinary notices, of which 12 involved public censures and 5 included unsuitability statements, according to the HKEX Enforcement Annual Report 2024. The trend accelerated in Q1 2025, with 8 public censures and 4 unsuitability statements, reflecting a deliberate policy shift toward naming individuals. The Listing Division’s 2025 Enforcement Priorities, released in December 2024, explicitly stated that “director accountability for systemic control failures will be a primary focus.”

The Process: From Investigation to Sanction

The disciplinary process begins with a referral from the Listing Division’s Surveillance Unit, which monitors issuer filings, media reports, and whistleblower complaints under the HKEX Whistleblowing Policy (effective March 2024). If a prima facie breach is identified, the Division issues a “show cause” letter under Listing Rule 2A.11, requiring the issuer or director to respond within 21 business days. The Listing Committee then holds a hearing, where the respondent may be represented by counsel. Decisions are published on the HKEX website within 14 days of the hearing.

A critical procedural point: the HKEX does not require the SFC’s consent to issue a public censure or unsuitability statement, though it coordinates with the SFC under the Memorandum of Understanding on Enforcement Cooperation (revised 2023). This means issuers face dual jeopardy—an HKEX sanction does not preclude SFC enforcement under the SFO.

Triggers for Public Censure and Unsuitability Statements

Disclosure Failures in IPO Prospectuses and Continuing Obligations

The most common trigger for public censure is material misstatements or omissions in IPO prospectuses or annual reports. Under Main Board Rule 11.07, a prospectus must contain “all information necessary to enable a reasonable investor to make an informed assessment of the issuer’s financial position.” In the 2024 case of HKEX Disciplinary Notice No. 12/2024, the Exchange publicly censured a Main Board-listed technology company for failing to disclose a related-party transaction valued at HKD 120 million in its 2023 annual report, a breach of Main Board Rule 14A.35. The directors were also issued unsuitability statements, with the lead director barred for three years.

Data from the HKEX’s 2024 Enforcement Report shows that 60% of public censures involved disclosure failures, with 40% of those cases including unsuitability statements. The Listing Division’s 2025 guidance, “Disclosure Obligations and Director Responsibilities” (March 2025), emphasizes that directors cannot delegate disclosure duties to company secretaries or auditors; they bear “ultimate responsibility” under Main Board Rule 3.08.

Internal control failures are the second-largest category, accounting for 30% of 2024 public censures. Under Main Board Rule 3.21, issuers must maintain “adequate internal controls” over financial reporting and operations. In HKEX Disciplinary Notice No. 7/2024, a GEM-listed pharmaceutical company was publicly censured after its internal audit revealed a HKD 50 million cash misappropriation by a senior manager, which the board had failed to detect for 18 months. The directors received unsuitability statements for two years, with the HKEX citing a “systemic failure of oversight.”

For sponsors, the SFC’s Code of Conduct (Chapter 17) imposes due diligence standards. In the 2024 SFC enforcement action against a mid-tier sponsor, the firm was fined HKD 45 million for failing to verify a client’s revenue recognition policy during an IPO, a breach of Paragraph 17.6(b) of the Code. The HKEX subsequently issued a public censure against the sponsor’s responsible officers under Listing Rule 3A.03.

Practical Implications for Issuers and Intermediaries

Director Liability and Board Composition

An unsuitability statement under Listing Rule 2A.09(5) has immediate and severe consequences. The named director must resign from all boards of HKEX-listed issuers within 14 days of the notice. Failure to comply results in the Exchange suspending trading in the issuer’s securities under Main Board Rule 6.01. In 2024, the HKEX suspended trading in three issuers whose directors refused to resign after unsuitability statements, with an average suspension period of 45 trading days.

For family offices and institutional investors, this creates a new due diligence requirement: screening director histories against the HKEX’s public disciplinary register, updated monthly. The register, accessible via the HKEX website, lists all unsuitability statements and their durations. As of June 2025, 22 directors are currently subject to active unsuitability statements, with an average term of 3.2 years.

Sponsors face dual regulatory risk: the SFC’s enforcement under the Code of Conduct and the HKEX’s disciplinary actions under the Listing Rules. The 2024 SFC fine of HKD 45 million set a benchmark, but the HKEX’s public censure of the same sponsor’s responsible officers carries reputational damage that can affect future IPO mandates. Data from Dealogic shows that sponsors with a public censure in the prior 12 months saw a 30% decline in IPO mandate wins in 2024.

Legal advisors, while not directly subject to Listing Rules, can be implicated under the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (Chapter 571, Section 169), which prohibits “knowing or reckless” assistance in breaches. In a 2023 case, a law firm was reprimanded by the SFC for drafting a prospectus that omitted a material litigation risk, resulting in a HKD 2 million fine.

Actionable Takeaways for Market Participants

Directors must conduct quarterly internal control reviews under Main Board Rule 3.21, documenting findings in board minutes to demonstrate proactive oversight.
Issuers should retain independent legal counsel for prospectus drafting and annual report review, ensuring compliance with Main Board Rule 11.07’s full disclosure requirements.
Sponsors must implement a two-tier due diligence process for revenue recognition and related-party transactions, aligning with SFC Code of Conduct Paragraph 17.6(b) and HKEX Listing Rule 14A.35.
Institutional investors should integrate the HKEX disciplinary register into their pre-investment screening, flagging any issuer with a director subject to an active unsuitability statement.
Company secretaries must ensure that all directors receive annual training on Listing Rule obligations, as the HKEX’s 2025 enforcement priorities explicitly include director education failures as a trigger for public censure.